Kayexalate Generic Name & Formulations
Sodium polystyrene sulfonate; pwd; sodium content 4.1mEq/g.
Cation exchange resin.
Limitations of Use
Not for treating life-threatening hyperkalemia due to its delayed onset of action.
Kayexalate Dosage and Administration
See full labeling. Oral: give in an upright position; 15g as a suspension 1–4 times daily. Rectal enema: 30–50g in 100mL every 6hrs.
See full labeling. 1g per 1mEq of potassium as basis of calculation may be used.
Obstructive bowel disease. Neonates with reduced gut motility.
Kayexalate Boxed Warnings
Avoid in patients at risk for constipation/impaction (eg, history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, bowel obstruction); discontinue if constipation develops. Post-surgery: avoid if have not had a bowel movement. CHF, hypertension, edema: monitor for fluid overload. Risk of aspiration. Monitor electrolytes (eg, potassium, calcium, magnesium). Neonates: do not give by oral route. Infants.
Increased risk of intestinal necrosis with concomitant sorbitol; not recommended. Separate dosing by ≥3hrs before or ≥3hrs after other oral drugs (6hrs in patients with gastroparesis). Increased risk of systemic alkalosis with nonadsorbable cation-donating antacids and laxatives. Reduces absorption of thyroxine, lithium.
Kayexalate Adverse Reactions
Anorexia, constipation, diarrhea, fecal impaction, GI concretions (bezoars), ischemic colitis, nausea, vomiting; intestinal necrosis, electrolyte disturbances.
Kayexalate Clinical Trials
Kayexalate Patient Counseling